Why BeyondSpring Inc.’s (BYSI) Stock Is Down 5.88%

By Jenna Brashear
April 15, 2026
Featured Tickers:

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BeyondSpring Inc. before investing.

In this article, we go over a few key elements for understanding BeyondSpring Inc.’s stock price such as:

  • BeyondSpring Inc.’s current stock price and volume
  • Why BeyondSpring Inc.’s stock price changed recently
  • Upgrades and downgrades for BYSI from analysts
  • BYSI’s stock price momentum as measured by its relative strength

About BeyondSpring Inc. (BYSI)

Before we jump into BeyondSpring Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Want to learn more about BeyondSpring Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BeyondSpring Inc..

Learn More About A+ Investor

BeyondSpring Inc.’s Stock Price as of Market Close

As of April 15, 2026, 2:47 PM, CST, BeyondSpring Inc.’s stock price was $1.690.

BeyondSpring Inc. is down 2.31% from its previous closing price of $1.730.

During the last market session, BeyondSpring Inc.’s stock traded between $1.690 and $1.740. Currently, there are approximately 40.68 million shares outstanding for BeyondSpring Inc..

BeyondSpring Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

BeyondSpring Inc. Stock Price History

BeyondSpring Inc.’s (BYSI) price is currently up 3.05% so far this month.

During the month of April, BeyondSpring Inc.’s stock price has reached a high of $1.840 and a low of $1.530.

Over the last year, BeyondSpring Inc. has hit prices as high as $3.440 and as low as $1.160. Year to date, BeyondSpring Inc.’s stock is up 3.68%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BeyondSpring Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 14, 2026, there were analysts who downgraded BeyondSpring Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate BeyondSpring Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BeyondSpring Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BeyondSpring Inc. (BYSI) by visiting AAII Stock Evaluator.

Relative Price Strength of BeyondSpring Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 14, 2026, BeyondSpring Inc. has a weighted four-quarter relative price strength of 10.60%, which translates to a Momentum Score of 78 and is considered to be Strong.

Want to learn more about how BeyondSpring Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BeyondSpring Inc. Stock Price: Bottom Line

As of April 15, 2026, BeyondSpring Inc.’s stock price is $1.690, which is down 2.31% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BeyondSpring Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
O'Neil CAN SLIM Screen: 38.3% Compared to S&P 500
at only 23.3%

Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.